Acorda Therapeutics: Multiple Sclerosis trials

The registry lists 10 Multiple Sclerosis studies with Acorda Therapeutics as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 1Phase 3 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)CompletedNCT01535664Results posted
• Study of Fampridine-ER Tablets in Patients With Multiple SclerosisCompletedNCT01328379Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00654927Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 TrialCompletedNCT00649792Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 TrialCompletedNCT00648908Phase 3Results posted
• Study of Fampridine-SR Tablets in Multiple Sclerosis PatientsCompletedNCT00483652Phase 3Results posted
• Study of Oral Fampridine-SR in Multiple SclerosisCompletedNCT00127530Phase 3Results posted
• Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00053417Phase 2Results posted
• An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a RelapseCompletedNCT02398461Phase 1
• An Intravenous Infusion Study of rHIgM22 in Patients With Multiple SclerosisCompletedNCT01803867Phase 1